Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 7;19(1):10.
doi: 10.1186/s12951-020-00745-9.

Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy

Sean Swetledge  1 , Jangwook P Jung  1 , Renee Carter  2 , Cristina Sabliov  3
Affiliations
Review

Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy

Sean Swetledge et al. J Nanobiotechnology. .

Abstract

Advantages of polymeric nanoparticles as drug delivery systems include controlled release, enhanced drug stability and bioavailability, and specific tissue targeting. Nanoparticle properties such as hydrophobicity, size, and charge, mucoadhesion, and surface ligands, as well as administration route and suspension media affect their ability to overcome ocular barriers and distribute in the eye, and must be carefully designed for specific target tissues and ocular diseases. This review seeks to discuss the available literature on the biodistribution of polymeric nanoparticles and discuss the effects of nanoparticle composition and administration method on their ocular penetration, distribution, elimination, toxicity, and efficacy, with potential impact on clinical applications.

Keywords: Drug delivery system; Ocular biodistribution; Ocular drug delivery; Polymeric nanoparticle.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Anatomy of the eye and administration routes
Fig. 2
Fig. 2
Nanoparticle trafficking routes in the eye
Fig. 3
Fig. 3
Blood-retinal barrier [65]. Permission to reproduce this figure is granted under the Creative Commons Attribution License. Figure 3 is reprinted from Frontiers in Immunology, Forrester V & Xu H, Good news–bad news: the Yin and Yang of immune privilege in the eye, 2012, under the Creative Commons Attribution License
Fig. 4
Fig. 4
a Retinal cross section of mouse eye showing gradients of fluorescence due to movement of nanoparticles, b Outer to inner gradient in fluorescence c Anterior to posterior gradient in fluorescence [26]. Permission to reproduce this figure has been obtained from Elsevier. Figure 4 is reprinted from Nanomedicine: Nanotechnology, Biology, and Medicine, 12/7, Mahaling B & Katti DS, Physicochemical properties of core–shell type nanoparticles govern their spatiotemporal biodistribution in the eye, 2149–60, 2016, with permission from Elsevier
See this image and copyright information in PMC

References

    1. Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888–e897. - PubMed
    1. Yavuz B, Kompella UB. Ocular drug delivery. Handb Exp Pharmacol. 2017;242:57–93. - PubMed
    1. Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017 doi: 10.1016/j.addr.2017.04.001. - DOI - PMC - PubMed
    1. Chen H, Jin YY, Sun L, Li X, Nan KH, Liu HH, et al. Recent developments in ophthalmic drug delivery systems for therapy of both anterior and posterior segment diseases. Colloid Interfac Sci. 2018;24:54–61.
    1. Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B. 2017;7(3):281–291. - PMC - PubMed